Zeltia Overview
- Year Founded
-
1939
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Financing Rounds
-
2
- Investments
-
3
Zeltia General Information
Description
Operator of a biopharmaceutical company dedicated to exploring the marine universe in search of innovative treatments. The company is carrying out a pioneering program in marine biotechnology for the discovery of new medicines of marine origin with antitumor activity for oncology, central nervous system, molecular diagnostics, and genetic identification and RNAi (RNA interference) illness treatments.
Contact Information
Website
www.zeltia.comCorporate Office
- Plaza del Descubridor Diego de Ordás
- 3, planta 5
- 28003 Madrid
- Spain
Corporate Office
- Plaza del Descubridor Diego de Ordás
- 3, planta 5
- 28003 Madrid
- Spain
Zeltia Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Zeltia Patents
Zeltia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2213286-A1 | N-(phenyl or pyridyl)prenylamine derivatives for the treatment of obesity, diabetes and cardiovascular diseases | Inactive | 02-Feb-2009 | ||
| WO-2010086454-A1 | N-(phenyl or pyridyl)prenylamine derivatives for the treatment of obesity, diabetes, cardiovascular diseases and other adiponectin-related diseases | Inactive | 02-Feb-2009 | ||
| WO-2010086454-A9 | N-(phenyl or pyridyl)prenylamine derivatives for the treatment of obesity, diabetes, cardiovascular diseases and other adiponectin-related diseases | Inactive | 02-Feb-2009 | ||
| EP-2020447-A1 | Method for identifying compounds modulating adiponectin gene expression | Inactive | 03-Aug-2007 | ||
| WO-2009019208-A1 | Method for identifying compounds modulating adiponectin gene expression | Inactive | 03-Aug-2007 | C12Q1/6883 |
Zeltia Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Zeltia Investments & Acquisitions (3)
Zeltia’s most recent deal was a Reverse Merger with Pharma Mar. The deal was made on 02-Nov-2014.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pharma Mar | 02-Nov-2014 | Reverse Merger | Other Pharmaceuticals and Biotechnology | ||
| Xylazel | 01-Jan-1999 | Merger/Acquisition | Specialty Chemicals | ||
| Xylazel | 01-Jan-1975 | Joint Venture | Specialty Chemicals |
Zeltia Exits (2)
Zeltia’s most recent exit was on 01-Jan-1999 from Xylazel. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Xylazel | 01-Jan-1999 | Completed |
|
||
| Xylazel | 01-Jan-1975 | Joint Venture | Completed |
|
Zeltia FAQs
-
When was Zeltia founded?
Zeltia was founded in 1939.
-
Where is Zeltia headquartered?
Zeltia is headquartered in Madrid, Spain.
-
What industry is Zeltia in?
Zeltia’s primary industry is Biotechnology.
-
Is Zeltia a private or public company?
Zeltia is a Private company.
-
What is Zeltia’s current revenue?
The current revenue for Zeltia is .
-
Who are Zeltia’s investors?
Pharma Mar has invested in Zeltia.
-
When was Zeltia acquired?
Zeltia was acquired on 02-Nov-2014.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process